Enjoy complimentary customisation on priority with our Enterprise License!
The herpes treatment market is estimated to decline at a CAGR of 3.76% between 2022 and 2027. The herpes treatment market size is forecast to increase by USD 920.28 million. The growth of the market depends on several factors, including the increasing prevalence of herpes infection, the large patient pool, and the rising prevalence rate of shingles in the older population.
This market report extensively covers market segmentation by Product (vaccination and drug therapy), Type (herpes zoster and herpes simplex), and geography North America, Europe, Asia, and Rest of World (ROW). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, Download Report Sample
Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increasing prevalence of herpes infection is a major factor driving the global herpes simplex virus treatment market share growth. Apart from traditional risk factors such as sexual or physical contact with the infected person, there have been several other factors contributing to the rising prevalence of herpes. People with a weaker immune system due to the intake of immunosuppressants for an organ transplant are vulnerable to herpes infection. They are one of the major factors for the increasing prevalence of herpes.
The immunocompromised status is assumed to be more vulnerable to catching this viral infection. Also, people with HIV AIDS, and organ transplants are at higher risk of developing herpes. Regardless of the great advances in organ transplantation in the last few decades, herpesvirus infections continue to be a major cause of mortality and morbidity for a large number of transplant recipients. Due to such reasons, the market will continue to grow significantly during the forecast period.
The emergence of novel therapies is the primary trend for the global herpes simplex virus treatment market share growth. High dependency on a limited number of therapies is a major challenge being faced by the market. For instance, genital and oral herpes at present do not have any cure; the disease can only be managed by the available treatment options. Several studies are under trial, and the emergence of better therapies is expected in the coming times. The major drugs present for the treatment of genital herpes control the outbreaks of the disease but not the shedding.
To overcome such limitations, research is underway to develop novel treatment options. For instance, Genocea is developing a GEN-003 vaccine. At present, it is under clinical trials and has been found to be effective in controlling both the shedding and outbreak of HSV-2 infection. GEN-003 is therapeutic in nature, and it is effective only for individuals who are already infected with the virus. Trials to prevent the infection is also under consideration. The advent of such novel therapies will potentially improve the treatment facilities for the disease.
The highly genericized market will be a major challenge for the global herpes simplex virus treatment market share growth during the forecast period. The market is highly generic in nature owing to the patent expiry, and hence, the introduction of generics. The generic market is attaining a deeper market penetration due to support from various governmental and non-governmental organizations. The lower prices of these generic drugs have led to their wider adoption. However, this has increased the price competition in the industry and lowered the overall revenue generated by the vendors dealing in the branded drugs market.
Generic substitution has been introduced in about 22 European countries and many states in the US. This has been done with the motive to increase the dispensing of generic medicines and decrease the cost of pharmaceutical products. Generic substitution has successfully increased the penetration of generic drugs and reduced the overall growth of pharmaceutical expenses by individuals. Such instances of volume replacing value due to the prevalence of generics in the market remain a growth hurdle.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Herpes Treatment Market Customer Landscape
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the herpes simplex virus treatment market.
Abbvie - The company offers herpes treatment called RINVOQ as monotherapy or with topical corticosteroid applications.
The herpes treatment market report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The herpes simplex virus treatment market share growth by the vaccination segment will be significant during the forecast period. Vaccines are among the most important biological therapies that help in the prevention of various disease outbreaks. The significance of the use of vaccines is that they can provide active immunization, wherein dead or live microbial antigens are administered to individuals before they are naturally infected by the antigen. After immunization, if the person gets infected by that antigen, there will be sufficient antibodies (because of active immunization) present in the body, which will rapidly eliminate that antigen.
Get a glance at the market contribution of various segments View PDF Sample
The vaccination segment was valued at USD 1,998.08 million in 2017 and continued to grow by 2021. The governments of various developing and underdeveloped economies are providing vaccines for various treatments, including herpes, at subsidized rates to people. The fund provided by the government is almost 100% in about 115 countries across the world. However, it is between 50%-100% in about 20 countries. Moreover, the efforts of organizations such as the WHO and the United Nations International Children's Emergency Fund (UNICEF) in creating awareness of vaccination among community members are likely to propel the growth of the vaccination segment of the global herpes simplex virus treatment market during the forecast period.
For more insights on the market share of various regions View PDF Sample now!
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the herpes simplex virus treatment market during the forecast period.
The market in this region is primarily driven by the sales of drugs and vaccines used in the treatment/prophylaxis of herpes. North America is dominating the global market also due to its established healthcare infrastructure and the growing prevalence of herpes. The growing rate of the geriatric population is helping the market sustain its growth. The disease is very common in people aged 50 years and above due to a weakened immune system. The development of shingles leads to further complications such as PHN, a major complication of shingles that leads to severe pain in the areas where the rashes occur. Therefore, therapeutic advancement and a highly focused research approach for drug development for herpes are required to cater to this huge population's needs. The growth of the market in this region is also attributed to increased investments in R and D by large pharmaceutical companies and the presence of a proper regulatory framework for the approval of new drugs in the region.
This report forecasts the contribution of all the segments to the growth of the market. In addition, we have included the COVID-19 impact and the recovery strategies for each segment. COVID-19 led to an upsurge in the demand for North America. However, with the lifting of the lockdown restrictions due to the initiation of vaccination drives in the second half of 2020, clinics and hospitals offering treatment for herpes resumed their operations in the first half of 2021, which is expected to drive the demand for drugs used for herpes treatment during the forecast period. Moreover, pharmaceutical companies are investing heavily in R and D to find a feasible way to treat herpes. Hence, the increasing adoption of herpes treatment, a rise in healthcare expenditure, growth in the number of advanced healthcare facilities, and investments by vendors in the market are expected to recover and stabilize the growth of the herpes simplex virus treatment market in North America during the forecast period.
The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Herpes Treatment Market Scope |
|
Report Coverage |
Details |
Page number |
160 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Decelerate at a CAGR of 3.76% |
Market growth 2023-2027 |
USD 920.28 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
4.05 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 41% |
Key countries |
US, Germany, France, UK, and Japan |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., AiCuris Anti infective Cures AG, Aurobindo Pharma Ltd., Avet Pharmaceuticals Inc., Cadila Healthcare Ltd., CENTURION REMEDIES Pvt. Ltd., Cipla Ltd., Eli Lilly and Co., Fresenius SE & Co. KGaA, Gilead Sciences Inc., GlaxoSmithKline Plc, Maruho Co. Ltd., Merck and Co. Inc., Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Zeelab Laboratories Ltd., and Bausch Health Co Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Get access to Report Sample PDF !
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.